View Older Stories View More Recent Stories

Dec 10, 2024 08:00AM Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cr
Dec 4, 2024 08:04AM Dare Bioscience (DARE) Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Dec 4, 2024 08:00AM Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Nov 14, 2024 04:01PM Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Nov 13, 2024 08:07AM Dare Bioscience (DARE) Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene Pivotal Study Clinical Trial Sites
Nov 13, 2024 08:00AM Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Nov 7, 2024 08:00AM Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
Oct 23, 2024 12:34PM Dare Bioscience (DARE) Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Oct 23, 2024 12:30PM Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Oct 21, 2024 08:05AM Dare Bioscience (DARE) Announces $15M Common Stock Purchase Agreement with Lincoln Park Capital Fund
Oct 21, 2024 08:05AM Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Aug 26, 2024 08:03AM Dare Bioscience (DARE) Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 26, 2024 08:00AM Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 13, 2024 08:19AM Dare Bioscience (DARE) Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 13, 2024 08:00AM Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 12, 2024 04:01PM Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Aug 5, 2024 08:00AM Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024
Jul 19, 2024 08:00AM Dare Bioscience (DARE) Regains Nasdaq Compliance
Jul 19, 2024 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Jul 1, 2024 06:54AM Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Jun 27, 2024 08:04AM Dare Bioscience (DARE) Announces 1:12 Reverse Share Split
Jun 27, 2024 08:00AM Daré Bioscience Announces Reverse Stock Split
Jun 24, 2024 08:00AM Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
May 14, 2024 08:00AM Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
May 7, 2024 08:00AM Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
May 2, 2024 08:00AM Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Apr 30, 2024 07:30AM Dare Bioscience (DARE) Secures $22M in Non-Dilutive Strategic Royalty Financing
Apr 30, 2024 07:30AM Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Apr 23, 2024 08:03AM Dare Bioscience (DARE) Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Apr 23, 2024 08:00AM Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Apr 11, 2024 08:00AM Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intrava
Mar 28, 2024 08:00AM Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Mar 21, 2024 08:00AM Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Feb 22, 2024 08:00AM Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Jan 31, 2024 08:05AM Dare Bioscience (DARE) Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream
Jan 31, 2024 08:00AM Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Jan 26, 2024 04:34PM Dare Bioscience (DARE) Announces Board Changes
Jan 26, 2024 04:30PM Daré Bioscience Announces Executive Team and Board of Directors Changes
Jan 17, 2024 08:05AM Dare Bioscience (DARE) Announces Grant to Support Biotherapeutic Product Development
Jan 17, 2024 08:00AM Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Jan 4, 2024 08:07AM Dare Bioscience (DARE) DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Jan 4, 2024 08:00AM Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Dec 26, 2023 08:00AM Dare Bioscience (DARE) Secures $12M in Royalty-backed Investment Structure
Dec 26, 2023 08:00AM Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Dec 20, 2023 08:02AM Dare Bioscience (DARE) Reports Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Study
Dec 20, 2023 08:00AM Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Dec 13, 2023 08:01AM Dare Bioscience (DARE) Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DA
Dec 13, 2023 08:00AM Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB
Dec 7, 2023 08:08AM Dare Bioscience (DARE) Announces FDA Clearance of IND Application for DARE-VVA1
Dec 7, 2023 08:00AM Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vul
View More Recent Stories View Older Stories